Form 4: uniQure Executive Sells Shares Under 10b5-1 Plan

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., reported transactions involving the sale of ordinary shares and the acquisition of stock options under a pre-arranged trading plan.

Summary

• Walid Abi-Saab, Chief Medical Officer of uniQure N.V., executed a series of transactions on June 30, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 26, 2025.
• Abi-Saab acquired 10,000 ordinary shares at a price of $5.59 per share.
• Concurrently, 10,000 ordinary shares were sold at a weighted average price of $46.46, with individual sales ranging from $46.19 to $46.97.
• An additional 20,000 ordinary shares were sold at a weighted average price of $46.40, with prices ranging from $46.24 to $46.80.
• Following these transactions, Abi-Saab beneficially owns 148,235 ordinary shares directly.
• A stock option to purchase 10,000 ordinary shares at an exercise price of $5.59 was also acquired, with vesting commencing March 1, 2034.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant sale of shares by a key executive, despite being executed under a 10b5-1 plan. The acquisition of options provides a minor positive offset.

Positives

• The reporting person acquired stock options, indicating continued equity participation.
• The transactions were executed under a Rule 10b5-1 plan, suggesting pre-planned and potentially less market-impactful trading activity.

Negatives

• A significant number of ordinary shares (30,000 in total) were sold by a key executive.
• The sale of shares at prices significantly higher than the acquisition price of the options could be interpreted as profit-taking.

Risks

• The sale of a substantial number of shares by a Chief Medical Officer could be perceived negatively by the market, potentially signaling a lack of confidence, although executed under a 10b5-1 plan.
• Future stock price performance may be influenced by the perception of insider selling, even if pre-planned.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. The future outlook is primarily related to the vesting schedule of the stock option granted.

Management Comments

• The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
• The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors. While this filing details sales under a pre-arranged 10b5-1 plan, which is designed to mitigate concerns about insider trading, the volume of shares sold by a senior executive can still influence market perception. The gene therapy sector, where uniQure operates, is characterized by high R&D costs and significant binary events related to clinical trial outcomes and regulatory approvals, making executive confidence signals particularly relevant.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a senior executive as a negative signal, potentially impacting short-term stock price, although the 10b5-1 plan mitigates insider trading concerns.
• Employees: May observe executive trading patterns as an indicator of company outlook.
• Management: The transactions reflect the executive's personal financial planning and diversification strategy.

Next Steps

• The stock option granted on March 1, 2024, will continue to vest quarterly until fully vested.
• The reporting person may continue to execute transactions under the Rule 10b5-1 plan if it remains active.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established 10b5-1 plan. While the sale of 30,000 shares by a senior executive is notable, the plan's structure suggests it's not necessarily a reflection of negative non-public information. The acquisition of stock options indicates continued alignment with the company's long-term prospects. Given the lack of company-specific performance data in this filing and the pre-planned nature of the sales, a 'hold' recommendation is appropriate, pending further company disclosures.

Keywords

uniQure, QURE, Form 4, Insider Trading, Stock Options, Share Sales, Rule 10b5-1, Walid Abi-Saab, Chief Medical Officer, Beneficial Ownership